美国常规分割与大分割质子放疗用于乳房切除术后放疗的随机2期试验(MC1631)
在Mayo Clinic两院区开展的随机2期试验,88例乳房切除术后有放疗指征的患者按1:1分配至常规分割(50 Gy/25次)或大分割(40.05 Gy/15次)质子放疗组。中位随访39.3个月时,24个月并发症率常规组15% vs 大分割组20%,绝对差异4.9%(单侧95%CI上限18.5,p=0.27),未能确立大分割的非劣效性;但耐受性相似,作者认为值得进一步研究。
要点
- 大分割质子乳房切除术后放疗24个月并发症率20% vs 常规分割15%,绝对差异4.9%(单侧95%CI上限18.5),非劣效性未能确立。
- 所有14例方案定义的并发症均发生在即刻扩张器或假体植入重建的患者中。
- 大分割组8例并发症均为感染,常规组为包膜挛缩5例和脂肪坏死1例需手术干预。
核心结论
- 中位随访39.3个月后,大分割质子乳房切除术后放疗的非劣效性未能确立;但鉴于耐受性相似,作者认为大分割质子放疗值得在有或无即刻重建的患者中进一步研究。
研究设计与样本
- 在Mayo Clinic罗切斯特院区和亚利桑那院区开展的随机2期试验(MC1631),比较常规分割(50 Gy/25次,每次2 Gy,相对生物效应1.1)与大分割(40.05 Gy/15次,每次2.67 Gy,相对生物效应1.1)质子乳房切除术后放疗,均采用笔束扫描技术。
- 入组标准为年龄18岁及以上、ECOG体能状态0-2分、乳房切除术后有放疗指征(伴或不伴即刻重建);按1:1随机分配,以是否即刻重建为分层因素,采用偏币最小化算法。
- 2016年6月2日至2018年8月23日共随机88例(每组44例),其中82例接受方案治疗(常规组41例,大分割组41例);中位年龄52岁(IQR 44-64),79例(96%)为白人,2例(2%)为黑人或非裔美国人,1例(1%)为亚裔,79例(96%)为非西班牙裔。
- 主要终点为自首次放疗起24个月并发症率,定义为末次放疗90天后发生的3级或更严重不良事件,或即刻重建患者中计划外手术干预;若两组24个月并发症率差异的单侧95%CI上限大于10%,则不能排除大分割的劣效性。
主要发现
- 截至数据截止日2023年1月30日,中位随访39.3个月(IQR 37.5-61.2);平均心脏剂量中位数常规组为0.54 Gy(IQR 0.30-0.72),大分割组为0.49 Gy(IQR 0.25-0.64)。
- 首次放疗后24个月内,常规分割组6例(15%)患者发生14例次方案定义的并发症,大分割组8例(20%)患者发生8例次,绝对差异4.9%(单侧95%CI上限18.5),p=0.27。
- 常规分割组并发症为需手术干预的包膜挛缩(41例中5例,12%)和脂肪坏死(1例,2%);大分割组8例并发症均为感染,其中3例为需手术干预的急性感染,5例为迟发感染(其中4例需手术干预)。
- 所有14例并发症均发生于即刻扩张器或假体植入重建的患者。
关键数值与推荐
- 非劣效性界值:两组24个月并发症率差异的单侧95%CI上限大于10%则不能排除大分割的劣效性。
- 常规分割剂量:50 Gy分25次,每次2 Gy(相对生物效应1.1);大分割剂量:40.05 Gy分15次,每次2.67 Gy(相对生物效应1.1)。
临床怎么用
- 作者认为,鉴于耐受性相似,大分割质子乳房切除术后放疗值得在有或无即刻重建的患者中进一步研究。
局限性
- 中位随访39.3个月后,大分割组的非劣效性未能确立。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Proton therapy is under investigation in breast cancer as a strategy to reduce radiation exposure to the heart and lungs. So far, studies investigating proton postmastectomy radiotherapy (PMRT) have used conventional fractionation over 25-28 days, but whether hypofractionated proton PMRT is feasible is unclear. We aimed to compare conventional fractionation and hypofractionation in patients with indications for PMRT, including those with immediate breast reconstruction. METHODS: We did a randomised phase 2 trial (MC1631) at Mayo Clinic in Rochester (MN, USA) and Mayo Clinic in Arizona (Phoenix, AZ, USA) comparing conventional fractionated (50 Gy in 25 fractions of 2 Gy [relative biological effectiveness of 1·1]) and hypofractionated (40·05 Gy in 15 fractions of 2·67 Gy [relative biological effectiveness of 1·1]) proton PMRT. All patients were treated with pencil-beam scanning. Eligibility criteria included age 18 years or older, an Eastern Cooperative Oncology Group performance status of 0-2, and breast cancer resected by mastectomy with or without immediate reconstruction with indications for PMRT. Patients were randomly assigned (1:1) to either conventional fractionation or hypofractionation, with presence of immediate reconstruction (yes vs no) as a stratification factor, using a biased-coin minimisation algorithm. Any patient who received at least one fraction of protocol treatment was evaluable for the primary endpoint and safety analyses. The primary endpoint was 24-month complication rate from the date of first radiotherapy, defined as grade 3 or worse adverse events occurring from 90 days after last radiotherapy or unplanned surgical interventions in patients with immediate reconstruction. The inferiority of hypofractionation would not be ruled out if the upper bound of the one-sided 95% CI for the difference in 24-month complication rate between the two groups was greater than 10%. This trial is registered with ClinicalTrials.gov, NCT02783690, and is closed to accrual. FINDINGS: Between June 2, 2016, and Aug 23, 2018, 88 patients were randomly assigned (44 to each group), of whom 82 received protocol treatment (41 in the conventional fractionation group and 41 in the hypofractionation group; median age of 52 years [IQR 44-64], 79 [96%] patients were White, two [2%] were Black or African American, one [1%] was Asian, and 79 [96%] were not of Hispanic ethnicity). As of data cutoff (Jan 30, 2023), the median follow-up was 39·3 months (IQR 37·5-61·2). The median mean heart dose was 0·54 Gy (IQR 0·30-0·72) for the conventional fractionation group and 0·49 Gy (0·25-0·64) for the hypofractionation group. Within 24 months of first radiotherapy, 14 protocol-defined complications occurred in six (15%) patients in the conventional fractionation group and in eight (20%) patients in the hypofractionation group (absolute difference 4·9% [one-sided 95% CI 18·5], p=0·27). The complications in the conventionally fractionated group were contracture (five [12%] of 41 patients]) and fat necrosis (one [2%] patient) requiring surgical intervention. All eight protocol-defined complications in the hypofractionation group were due to infections, three of which were acute infections that required surgical intervention, and five were late infections, four of which required surgical intervention. All 14 complications were in patients with immediate expander or implant-based reconstruction. INTERPRETATION: After a median follow-up of 39·3 months, non-inferiority of the hypofractionation group could not be established. However, given similar tolerability, hypofractionated proton PMRT appears to be worthy of further study in patients with and without immediate reconstruction. FUNDING: The Department of Radiation Oncology, Mayo Clinic, Rochester, MN, the Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ, USA, and the US National Cancer Institute.
引用
- Mutter RW, Giri S, Fruth BF, et al. Conventional versus hypofractionated postmastectomy proton radiotherapy in the USA (MC1631): a randomised phase 2 trial. Lancet Oncol. 2023. PMID: 37696281. doi:10.1016/S1470-2045(23)00388-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。